Capital International Sarl increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,107 shares of the biopharmaceutical company’s stock after purchasing an additional 782 shares during the period. Capital International Sarl’s holdings in Gilead Sciences were worth $2,606,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Grove Bank & Trust bought a new stake in Gilead Sciences during the fourth quarter worth approximately $232,000. B. Riley Wealth Management Inc. increased its holdings in shares of Gilead Sciences by 19.7% in the fourth quarter. B. Riley Wealth Management Inc. now owns 9,101 shares of the biopharmaceutical company’s stock valued at $591,000 after buying an additional 1,496 shares in the last quarter. Malaga Cove Capital LLC increased its holdings in shares of Gilead Sciences by 19.8% in the fourth quarter. Malaga Cove Capital LLC now owns 18,607 shares of the biopharmaceutical company’s stock valued at $1,209,000 after buying an additional 3,069 shares in the last quarter. AMG National Trust Bank increased its holdings in shares of Gilead Sciences by 8.5% in the fourth quarter. AMG National Trust Bank now owns 74,817 shares of the biopharmaceutical company’s stock valued at $4,862,000 after buying an additional 5,861 shares in the last quarter. Finally, S.A. Mason LLC bought a new position in shares of Gilead Sciences in the fourth quarter valued at $60,000. 80.32% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ GILD traded up $2.13 on Thursday, hitting $71.79. 898,412 shares of the stock were exchanged, compared to its average volume of 30,795,556. Gilead Sciences, Inc. has a 52-week low of $60.89 and a 52-week high of $85.97. The company has a debt-to-equity ratio of 1.02, a current ratio of 3.10 and a quick ratio of 3.01. The company has a market capitalization of $90.65 billion, a price-to-earnings ratio of 16.99, a P/E/G ratio of 5.79 and a beta of 0.99. The company’s 50-day moving average price is $71.37 and its two-hundred day moving average price is $66.57.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a dividend of $0.68 per share. This represents a $2.72 annualized dividend and a yield of 3.79%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.63. The ex-dividend date of this dividend is Thursday, March 12th. Gilead Sciences’s payout ratio is presently 44.30%.
In other news, EVP Brett A. Pletcher sold 2,950 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $64.63, for a total transaction of $190,658.50. Following the transaction, the executive vice president now directly owns 20,014 shares in the company, valued at approximately $1,293,504.82. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director John Francis Cogan sold 2,413 shares of the business’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $75.27, for a total transaction of $181,626.51. Following the transaction, the director now owns 57,273 shares in the company, valued at $4,310,938.71. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 73,532 shares of company stock worth $5,101,386. 0.20% of the stock is currently owned by corporate insiders.
Several research firms have issued reports on GILD. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $80.00 price target on the stock in a report on Wednesday, March 18th. Wells Fargo & Co upped their price target on Gilead Sciences from $81.00 to $87.00 and gave the company an “overweight” rating in a report on Wednesday, March 4th. Barclays began coverage on Gilead Sciences in a report on Thursday, February 27th. They issued an “underweight” rating and a $62.00 price target on the stock. HC Wainwright cut Gilead Sciences from a “buy” rating to a “neutral” rating in a report on Monday, March 2nd. Finally, Cowen reaffirmed a “buy” rating and issued a $85.00 price target on shares of Gilead Sciences in a report on Thursday, January 2nd. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and fifteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $78.08.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Article: Insider Trading
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.